09.16.25
Blake Williamson, MD, MPH, invites Steven Dell, MD, to discuss the recent release of a new presbyopia drop—VIZZ (aceclidine ophthalmic solution, 1.44%; Lenz Therapeutics). Dr. Dell outlines why this drop represents a game-changing option for presbyopia therapy. The once-daily drop lasts for 10 hours and results in a sub-2-mm pupil size to achieve significant gains in near vision. They also review the innovation cycle of this product and how patients have responded to the treatment so far.
View full description +
Subscribe
08.25.25
Ushering in the Future of Cataract and Refractive SurgeryRobert J. Weinstock, MD; Gary Wörtz, MD; and Blake K. Williamson, MD, MPH
07.22.25
Potential Implications and Benefits of Direct SLT TechnologyJ. Morgan Micheletti, MD; Blake K. Williamson, MD, MPH; and Gary Wörtz, MD
06.06.25
Breaking Down the enVista Voluntary RecallCathleen McCabe, MD; Brent Saunders; Gary Wörtz, MD; and Blake K. Williamson, MD, MPH
05.20.25
The Highs and Lows of Turning an Idea Into a BusinessJohn P. Berdahl, MD; Blake Williamson, MD, MPH; and Gary Wörtz, MD
04.22.25
Innovative Technologies to Revolutionize PracticeI. Paul Singh, MD; Gary Wörtz, MD; and Blake Williamson, MD, MPH
03.26.25
Managing the Learning Curve as an Early AdopterWilliam Wiley, MD; Blake Williamson, MD, MPH; and Gary Wörtz, MD
02.20.25
The Current State of Multifocal and Trifocal IOL TechnologiesBlake Williamson, MD, MPH; Gary Wörtz, MD; and William Plauché, MD
Show More